• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

恶性疟原虫对乙胺嘧啶、周效磺胺、甲氧苄啶和磺胺甲恶唑单独及联合使用时的体外敏感性。

In vitro susceptibility of Plasmodium falciparum malaria to pyrimethamine, sulfadoxine, trimethoprim and sulfamethoxazole, singly and in combination.

作者信息

Petersen E

出版信息

Trans R Soc Trop Med Hyg. 1987;81(2):238-41. doi: 10.1016/0035-9203(87)90226-4.

DOI:10.1016/0035-9203(87)90226-4
PMID:3303480
Abstract

Two isolates of Plasmodium falciparum (F 32 and K 1) were tested against sulfadoxine (SDX), sulfamethoxazole (SMZ), pyrimethamine (PYR) and trimethoprim (TMP), using a 48 h microtest, with RPMI-1640 low in PABA and folic acid. The IC50 for F 32 was: PYR 6.1 X 10(-9) M (mol/litre), TMP 1.3 X 10(-7) M, Fansidar (SDX/PYR 80:1) less than 10(-8) to 1.3 X 10(-10) M and cotrimoxazole (SMZ/TMP 20:1) 2.6 X 10(-7) to 1.3 X 10(-8) M. The IC50 for K 1 was: PYR greater than 10(-6) M, TMP 8.2 X 10(-7) M, Fansidar 4.1 X 10(-7) to 1.1 X 10(-9) M and cotrimoxazole 1.8 X 10(-6) to 9.0 X 10(-8) M. The difference in IC50 between F 32 and K 1 against TMP and cotrimoxazole is much less than the difference between the IC50 values against PYR and Fansidar, indicating that cross-resistance between PYR and TMP exists, but is not complete. A method for calculating the IC50 by linear regression analysis is described.

摘要

使用含低对氨基苯甲酸(PABA)和叶酸的RPMI - 1640培养基,通过48小时微量试验,对两株恶性疟原虫(F 32和K 1)进行了磺胺多辛(SDX)、磺胺甲恶唑(SMZ)、乙胺嘧啶(PYR)和甲氧苄啶(TMP)的测试。F 32的半数抑制浓度(IC50)为:PYR 6.1×10⁻⁹ M(摩尔/升),TMP 1.3×10⁻⁷ M,Fansidar(SDX/PYR 80:1)小于10⁻⁸至1.3×10⁻¹⁰ M,复方新诺明(SMZ/TMP 20:1)2.6×10⁻⁷至1.3×10⁻⁸ M。K 1的IC50为:PYR大于10⁻⁶ M,TMP 8.2×10⁻⁷ M,Fansidar 4.1×10⁻⁷至1.1×10⁻⁹ M,复方新诺明1.8×10⁻⁶至9.0×10⁻⁸ M。F 32和K 1对TMP和复方新诺明的IC50差异远小于对PYR和Fansidar的IC50值差异,表明PYR和TMP之间存在交叉耐药性,但并不完全。描述了一种通过线性回归分析计算IC50的方法。

相似文献

1
In vitro susceptibility of Plasmodium falciparum malaria to pyrimethamine, sulfadoxine, trimethoprim and sulfamethoxazole, singly and in combination.恶性疟原虫对乙胺嘧啶、周效磺胺、甲氧苄啶和磺胺甲恶唑单独及联合使用时的体外敏感性。
Trans R Soc Trop Med Hyg. 1987;81(2):238-41. doi: 10.1016/0035-9203(87)90226-4.
2
Dihydrofolate reductase and dihydropteroate synthase genotypes associated with in vitro resistance of Plasmodium falciparum to pyrimethamine, trimethoprim, sulfadoxine, and sulfamethoxazole.与恶性疟原虫对乙胺嘧啶、甲氧苄啶、磺胺多辛和磺胺甲恶唑的体外抗性相关的二氢叶酸还原酶和二氢蝶酸合酶基因型。
Am J Trop Med Hyg. 2003 May;68(5):586-9. doi: 10.4269/ajtmh.2003.68.586.
3
In vitro activity of sulphamethoxazole/trimethoprim and sulfadoxine/pyrimethamine against Chlamydia trachomatis SA2f in McCoy cell culture.磺胺甲恶唑/甲氧苄啶和周效磺胺/乙胺嘧啶在 McCoy 细胞培养中对沙眼衣原体 SA2f 的体外活性。
Eur J Clin Microbiol Infect Dis. 1988 Jun;7(3):415-7. doi: 10.1007/BF01962352.
4
High prevalence of markers for sulfadoxine and pyrimethamine resistance in Plasmodium falciparum in the absence of drug pressure in the Ashanti region of Ghana.在加纳阿散蒂地区没有药物压力的情况下,恶性疟原虫中磺胺多辛和乙胺嘧啶耐药性标志物的高流行率。
Antimicrob Agents Chemother. 2005 Mar;49(3):1101-5. doi: 10.1128/AAC.49.3.1101-1105.2005.
5
Efficacy of Fansidar against Plasmodium falciparum in continuous culture.Fansidar对恶性疟原虫连续培养的疗效。
Am J Trop Med Hyg. 1982 Sep;31(5):913-8. doi: 10.4269/ajtmh.1982.31.913.
6
In vitro susceptibility of Plasmodium falciparum collected from pyrimethamine-sulfadoxine sensitive and resistant areas in Thailand.从泰国乙胺嘧啶-磺胺多辛敏感和耐药地区采集的恶性疟原虫的体外药敏试验
Bull World Health Organ. 1985;63(3):597-602.
7
Evaluation of an in vitro test method for the assessment of sensitivity of Plasmodium falciparum to pyrimethamine and sulfadoxine.评估恶性疟原虫对乙胺嘧啶和磺胺多辛敏感性的体外试验方法
Bull World Health Organ. 1987;65(3):345-52.
8
Fansidar-resistant falciparum malaria in Papua New Guinea.巴布亚新几内亚出现对Fansidar耐药的恶性疟原虫疟疾。
Lancet. 1980 Dec 6;2(8206):1243. doi: 10.1016/s0140-6736(80)92497-6.
9
[Chloroquine and fansidar resistance of Plasmodium falciparum now also in Ghana].[加纳现也出现恶性疟原虫对氯喹和 Fansidar 的耐药性]
Angew Parasitol. 1988 Nov;29(4):211-3.
10
Fansidar resistant falciparum malaria in Indonesia.
Lancet. 1979 Sep 15;2(8142):580-1. doi: 10.1016/s0140-6736(79)91633-7.

引用本文的文献

1
Repurposing Drugs to Fight Hepatic Malaria Parasites.重新利用药物来对抗肝疟疾寄生虫。
Molecules. 2020 Jul 28;25(15):3409. doi: 10.3390/molecules25153409.
2
Natural Product Inspired Novel Indole based Chiral Scaffold Kills Human Malaria Parasites via Ionic Imbalance Mediated Cell Death.天然产物启发的新型吲哚手性支架通过离子失衡介导的细胞死亡杀死人类疟疾寄生虫。
Sci Rep. 2019 Nov 28;9(1):17785. doi: 10.1038/s41598-019-54339-z.
3
Sulfamethoxazole Levels in HIV-Exposed Uninfected Ugandan Children.HIV 暴露未感染乌干达儿童的磺胺甲恶唑水平。
Am J Trop Med Hyg. 2018 Jun;98(6):1718-1721. doi: 10.4269/ajtmh.17-0933. Epub 2018 Apr 19.
4
Exploring anti-malarial potential of FDA approved drugs: an in silico approach.探索美国食品药品监督管理局批准药物的抗疟潜力:一种计算机模拟方法。
Malar J. 2017 Jul 18;16(1):290. doi: 10.1186/s12936-017-1937-2.
5
HIV treatments have malaria gametocyte killing and transmission blocking activity.HIV 治疗方法具有疟原虫配子体杀伤和传播阻断活性。
J Infect Dis. 2013 Jul;208(1):139-48. doi: 10.1093/infdis/jit132. Epub 2013 Mar 28.
6
Safety and efficacy of co-trimoxazole for treatment and prevention of Plasmodium falciparum malaria: a systematic review.复方新诺明治疗和预防恶性疟原虫疟疾的安全性和疗效:系统评价。
PLoS One. 2013;8(2):e56916. doi: 10.1371/journal.pone.0056916. Epub 2013 Feb 22.
7
HIV nonnucleoside reverse transcriptase inhibitors and trimethoprim-sulfamethoxazole inhibit plasmodium liver stages.HIV 非核苷类逆转录酶抑制剂和甲氧苄啶-磺胺甲噁唑抑制疟原虫肝期。
J Infect Dis. 2012 Dec 1;206(11):1706-14. doi: 10.1093/infdis/jis602.
8
Marked reduction in prevalence of malaria parasitemia and anemia in HIV-infected pregnant women taking cotrimoxazole with or without sulfadoxine-pyrimethamine intermittent preventive therapy during pregnancy in Malawi.在马拉维,接受复方磺胺甲噁唑与或不与磺胺多辛-乙胺嘧啶间歇性预防疗法的 HIV 感染孕妇中,疟疾寄生虫血症和贫血的患病率显著降低。
J Infect Dis. 2011 Feb 15;203(4):464-72. doi: 10.1093/infdis/jiq072. Epub 2011 Jan 7.
9
Therapeutic efficacy of sulphadoxine-pyrimethamine and chloroquine for the treatment of uncomplicated malaria in pregnancy in Burkina Faso.磺胺多辛-乙胺嘧啶和氯喹治疗布基纳法索妊娠期单纯性疟疾的疗效
Malar J. 2006 Jun 15;5:49. doi: 10.1186/1475-2875-5-49.
10
Impact of trimethoprim-sulfamethoxazole prophylaxis on falciparum malaria infection and disease.甲氧苄啶-磺胺甲恶唑预防对恶性疟原虫感染和疾病的影响。
J Infect Dis. 2005 Nov 15;192(10):1823-9. doi: 10.1086/498249. Epub 2005 Oct 13.